Galmed Pharmaceuticals Stock Pattern Recognition Hammer
| GLMD Stock | USD 0.63 0.0039 0.62% |
| Symbol |
Recognition |
The output start index for this execution was eleven with a total number of output elements of fifty. The function generated a total of three valid pattern recognition events for the selected time horizon. The Hammer describes Galmed Pharmaceuticals bullish reversal pattern.
Galmed Pharmaceuticals Technical Analysis Modules
Most technical analysis of Galmed Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Galmed from various momentum indicators to cycle indicators. When you analyze Galmed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. Market structure and macro sensitivity help explain how Galmed Pharmaceuticals behaves across regimes. Defensive traits reduce macro sensitivity. Galmed Pharmaceuticals has a market cap of 4.03 M, ROE of -46.34%. 
Rifka Kats ยท Member of Macroaxis Editorial Board
Methodology
Unless otherwise specified, financial data for Galmed Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Galmed (USA Stocks:GLMD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Galmed Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Galmed Stock is Curated By:
Rifka Kats ยท Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Galmed Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Galmed Pharmaceuticals' short interest history, or implied volatility extrapolated from Galmed Pharmaceuticals options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | FinTech Invested over 20 shares | |
 | Hedge Favorites Invested over 40 shares | |
 | Warren Buffett Holdings Invested over 60 shares | |
 | Impulse Invested over 200 shares | |
 | Adviser Favorites Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | ESG Investing Invested few shares | |
 | Momentum Invested over 20 shares | |
 | Cash Cows Invested few shares | |
 | Disruptive Technologies Invested few shares | |
 | Advertising Invested few shares | |
More Resources for Galmed Stock Analysis
A comprehensive view of Galmed Pharmaceuticals starts with financial statements and ratio context. Ratio context helps frame profitability, efficiency, and growth trends for Galmed Pharmaceuticals Stock. Selected reports below provide context for Galmed Stock:Galmed Pharmaceuticals has a market cap of 4.03 M, ROE of -46.34%. Review Risk vs Return Analysis for broader portfolio context. This reflects a position in Galmed Pharmaceuticals within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Before investing in Galmed Stock, review our How to Buy Galmed Pharmaceuticals guide for key considerations.Analysis related to Galmed Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Galmed Pharmaceuticals market price can diverge from book value, the accounting figure shown on Galmed balance sheet. Galmed Pharmaceuticals' market capitalization is 4.03 M. A P/B ratio of 0.21 suggests Galmed Pharmaceuticals trades near or below book value. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
It is useful to distinguish Galmed Pharmaceuticals' value from its trading price, which are computed with different methods. For Galmed Pharmaceuticals, key inputs include a P/B ratio of 0.21, and ROE of -46.34%. The quoted price is simply the exchange level where supply meets demand.